DE69636514D1 - Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen - Google Patents

Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen

Info

Publication number
DE69636514D1
DE69636514D1 DE69636514T DE69636514T DE69636514D1 DE 69636514 D1 DE69636514 D1 DE 69636514D1 DE 69636514 T DE69636514 T DE 69636514T DE 69636514 T DE69636514 T DE 69636514T DE 69636514 D1 DE69636514 D1 DE 69636514D1
Authority
DE
Germany
Prior art keywords
tumor treatment
human lymphocyte
patient
treatment
alloactivated human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636514T
Other languages
English (en)
Inventor
A Granger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69636514D1 publication Critical patent/DE69636514D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69636514T 1995-03-17 1996-03-15 Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen Expired - Lifetime DE69636514D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40638895A 1995-03-17 1995-03-17
PCT/US1996/003621 WO1996029394A1 (en) 1995-03-17 1996-03-15 Method for treating tumors

Publications (1)

Publication Number Publication Date
DE69636514D1 true DE69636514D1 (de) 2006-10-19

Family

ID=23607777

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636514T Expired - Lifetime DE69636514D1 (de) 1995-03-17 1996-03-15 Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen

Country Status (11)

Country Link
US (2) US5837233A (de)
EP (1) EP0815204B1 (de)
JP (1) JP3201610B2 (de)
KR (1) KR19980703072A (de)
AT (1) ATE338813T1 (de)
AU (1) AU696572B2 (de)
BR (1) BR9607894A (de)
CA (1) CA2214503C (de)
DE (1) DE69636514D1 (de)
NO (1) NO974275L (de)
WO (1) WO1996029394A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6203787B1 (en) 1997-10-10 2001-03-20 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
JP2001509135A (ja) * 1996-10-11 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法
WO1998048000A2 (en) * 1997-04-23 1998-10-29 The Regents Of The University Of California A cell strain with activated anti-cancer cytotoxic activity
WO1999018980A1 (en) * 1997-10-10 1999-04-22 Meyer Pharmaceuticals, Llc Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy
AU9794698A (en) * 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
CA2367132A1 (en) 1999-03-24 2000-09-28 Gene M. Shearer Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
US6719805B1 (en) * 1999-06-09 2004-04-13 C. R. Bard, Inc. Devices and methods for treating tissue
US20060009393A1 (en) * 1999-10-02 2006-01-12 The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
JP2004523202A (ja) * 2000-06-09 2004-08-05 ウニベルジテートスクリーニクム シャリテー メディツィニーシェ ファクルテート デル フンボルト−ウニベルジテート ツー ベルリン，アカデミッシェ ファーバルツング−フォルシュン 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用
DE10120505A1 (de) * 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
AU2003230553B2 (en) * 2002-02-22 2008-08-21 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US8691568B2 (en) 2006-11-22 2014-04-08 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
EP2117305A4 (de) * 2007-01-26 2011-03-30 Univ Louisville Res Found Modifikation von exosomalen komponenten zur verwendung als impfstoff
MX2011009277A (es) * 2009-03-05 2011-12-16 Macrocure Ltd Composicion de leucocito activada.
CN102597222B (zh) 2009-10-27 2015-07-15 因缪尼卡姆股份公司 用于增殖抗原特异性t细胞的方法
BR112017009475B1 (pt) 2014-11-05 2021-10-05 Memorial Sloan Kettering Cancer Center Métodos de seleção de uma linhagem de células t e de um doador das mesmas, sistema de computador para selecionar uma linhagem de células t, meio legível por computador, uso de uma população de células t e método para a obtenção de uma linhagem de células t
US20200237904A1 (en) 2017-01-26 2020-07-30 Immune Therapeutics Inc. Methods and Compositions Useful for Treating Cancer
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038145A (en) * 1974-07-08 1977-07-26 Mead Johnson & Company Malignancy diagnostic method
US4677056A (en) * 1983-08-18 1987-06-30 Sloan-Kettering Institute For Cancer Research Monoclonal antibody subsetting human helper and killer T-cells and method
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
EP0552243B1 (de) * 1990-09-06 1996-11-27 Schering Corporation Verwendung von interleukin-4 zur behandlung der festen tumoren
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
MX9707077A (es) 1998-08-30
ATE338813T1 (de) 2006-09-15
EP0815204A1 (de) 1998-01-07
JP3201610B2 (ja) 2001-08-27
EP0815204B1 (de) 2006-09-06
CA2214503C (en) 2002-05-07
AU696572B2 (en) 1998-09-10
US6136306A (en) 2000-10-24
EP0815204A4 (de) 1999-04-14
WO1996029394A1 (en) 1996-09-26
CA2214503A1 (en) 1996-09-26
JPH11501656A (ja) 1999-02-09
NO974275L (no) 1997-10-15
NO974275D0 (no) 1997-09-16
AU5254796A (en) 1996-10-08
KR19980703072A (ko) 1998-09-05
US5837233A (en) 1998-11-17
BR9607894A (pt) 1999-06-01

Similar Documents

Publication Publication Date Title
DE69636514D1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
DE3888273T3 (de) Medizinischer Apparat zur Behandlung mit Ultraschall.
DE69527609D1 (de) Verfahren zur reduzierung der körperfettanteils bei tieren mit der verabreichungvon konjugiergter linolsäure
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
IL137848A0 (en) Indole-3-propionic acids, salts and esters thereof used as medicaments
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
NO933044L (no) Fremgangsmaate for behandling av osteoporose
DE3876756T2 (de) Vorrichtung zur gesteuerten freigabe und verabreichung von wirkstoffen an tierisches gewebe.
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE58908604D1 (de) Medizinisches Gerät zur Stimulation eines physiologischen Vorganges eines Lebewesens mit sich selbsttätig an die körperliche Aktivität des Lebewesens anpassender Stimulationsintensiät.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
ATE254451T1 (de) Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69108116D1 (de) Vorrichtung zur Stimulation lebenden Gewebes.
EA200100385A1 (ru) Композиция и способ лечения нарушения гемостаза у субъекта (варианты)
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus

Legal Events

Date Code Title Description
8332 No legal effect for de